Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...235236237238239240241242243244245...401402»
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
    Clinical, Journal:  Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil. (Pubmed Central) -  Nov 17, 2021   
    In the multivariate analysis, reduced OS was found in patients with ≥5% SML (HR: 2.03 (1.11-3.72), p = 0.0039). We describe the prognostic role of sarcopenia beyond second line treatment and analyze other factors, such as performance status, tumor histological differentiation or carcinoembryonic antigen level that could predict TT treatment response.
  • ||||||||||  Clinical, Journal:  Identifying preventative measures against frailty, locomotive syndrome, and sarcopenia in young adults: a pilot study. (Pubmed Central) -  Nov 17, 2021   
    [Conclusion] Only 40% of the participants did not meet the three diagnostic criteria. On the other hand, there were not many participants with sarcopenia and/or locomotive syndrome diagnoses, suggesting that the improvement in intrinsic skeletal muscle mass rather than physical function is important for healthy Japanese young adults and could possibly be protective against future mobility or muscle-loss disorders.
  • ||||||||||  Clinical, Journal:  Frailty in Patients With Inflammatory Bowel Disease. (Pubmed Central) -  Nov 17, 2021   
    For a beneficial effect on patient outcomes, it is important that clinicians familiarize themselves with the tools for assessing frailty and implement interventions aimed at mitigating the individual components of the frailty phenotype. This article examines the proposed mechanisms for an association between frailty and IBD, tools for assessment of frailty, and data involving the impact of frailty on outcomes in patients with IBD.
  • ||||||||||  bezafibrate / Generic mfg.
    Journal:  Overweight, Obesity, and Late-Life Sarcopenia Among Men With Cardiovascular Disease, Israel. (Pubmed Central) -  Nov 17, 2021   
    Low kidney function as assessed by eGFRcys was associated with muscle weakness in community-dwelling Japanese older adults. We found a positive association between obesity and late-life sarcopenia and suggest that obesity might be an important modifiable risk factor related to sarcopenia among men with cardiovascular disease.
  • ||||||||||  Clinical, Journal:  SARC-F for screening of sarcopenia among older adults with cancer. (Pubmed Central) -  Nov 17, 2021   
    We found a positive association between obesity and late-life sarcopenia and suggest that obesity might be an important modifiable risk factor related to sarcopenia among men with cardiovascular disease. One-third of older adults with cancer in this cohort screened positive for sarcopenia using the SARC-F screening questionnaire, and these positive scores are associated with geriatric assessment domain impairments, reduced health-related quality of life, increased emergency room visits, and inferior overall survival.
  • ||||||||||  Clinical, Journal:  Decreased continuous sitting time increases heart rate variability in patients with cardiovascular risk factors. (Pubmed Central) -  Nov 17, 2021   
    These results suggest that a decrease in sitting time might induce parasympathetic activity during sleep. Therefore, reducing continuous sitting time during the day might contribute, in part, to improving the prognosis of patients with cardiovascular risk factors not only by avoiding muscle loss but also by providing positive influences on parasympathetic tone during sleep.
  • ||||||||||  Clinical, Review, Journal:  Characteristics of resistance training-based programs in older adults with sarcopenia: Scoping review (Pubmed Central) -  Nov 17, 2021   
    This review characterized resistance training-based programs in older people with sarcopenia, highlighting the extension, frequency, duration, and intensity of these, as well the most frequently used outcome measures and instruments. These results could be useful for prescribing future resistance training-based programs in older adults with sarcopenia.
  • ||||||||||  Review, Journal:  MicroRNAs associated with signaling pathways and exercise adaptation in sarcopenia. (Pubmed Central) -  Nov 17, 2021   
    Aberrant expression of miRNAs contributes to the development of sarcopenia by regulating the expression of critical genes involved in age-related skeletal muscle mass loss. Here we have a review on the signaling pathways along with the miRNAs controlling their components expression and subsequently we provide a brief overview on the effects of exercise on expression pattern of miRNAs in sarcopenia.
  • ||||||||||  Review, Journal:  Analysis of the Impact of Selected Vitamins Deficiencies on the Risk of Disability in Older People. (Pubmed Central) -  Nov 17, 2021   
    A focused nutritional approach might improve the diagnosis of nutritional deficiencies and the initiation of appropriate clinical interventions for reducing the risk of frailty. Further comprehensive research programs on nutritional interventions are needed, with a view to lowering deficiencies in older people and thus decreasing the risk of frailty and sarcopenia.
  • ||||||||||  Sarcopenia as measured by temporalis muscle width is a predictor of survival in primary CNS lymphoma (Exhibit Hall D) -  Nov 16, 2021 - Abstract #SNO2021SNO_726;    
    Temporalis width was strongly associated with survival among all patients (χ2=15.5, p< 0.001) as well as patients 65 years or older (χ2=4.5, p=0.03). We conclude that sarcopenia as measured by temporalis muscle thickness is associated with survival in PCNSL and may be an important variable to consider in clinical trials and routine practice.
  • ||||||||||  Journal:  Nutrition in cirrhosis: Dos and Don'ts. (Pubmed Central) -  Nov 16, 2021   
    Therefore, the reintroduction of a correctly balanced AA supplementation in patients undergoing HD to prevent or halt decline of hypercatabolism into cachexia is recommended. No abstract available
  • ||||||||||  Review, Journal:  The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms. (Pubmed Central) -  Nov 16, 2021   
    The aim of this narrative review is to provide an update on the effects of glucose-lowering drugs on sarcopenia in individuals with T2DM, focusing on the parameters used to define sarcopenia: muscle strength (evaluated by handgrip strength), muscle quantity/quality (evaluated by appendicular lean mass or skeletal muscle mass and their indexes), and physical performance (evaluated by gait speed or short physical performance battery). Furthermore, we also describe the plausible mechanisms by which glucose-lowering drugs may impact on sarcopenia.
  • ||||||||||  Review, Journal:  The Therapeutic Intervention of Sex Steroid Hormones for Sarcopenia. (Pubmed Central) -  Nov 16, 2021   
    The potential benefits and future research emphasis of each sex steroid hormone therapeutic intervention (testosterone, SARMs, estrogen, SERMs, DHEA, and progesterone) for sarcopenia are discussed. Enhanced understanding of the role of sex steroid hormones in the treatment for sarcopenia could lead to the development of hormone therapeutic approaches in combination with specific exercise and nutrition regimens.
  • ||||||||||  Trial completion date, Trial primary completion date:  Pulmonary Rehabilitation in End-Stage Liver Disease (clinicaltrials.gov) -  Nov 15, 2021   
    P=N/A,  N=50, Recruiting, 
    Enhanced understanding of the role of sex steroid hormones in the treatment for sarcopenia could lead to the development of hormone therapeutic approaches in combination with specific exercise and nutrition regimens. Trial completion date: Oct 2021 --> Dec 2022 | Trial primary completion date: Oct 2021 --> Dec 2022
  • ||||||||||  Biomarker, Retrospective data, Review, Journal:  A systematic review and meta-analysis of sarcopenia as a prognostic factor in gynecological malignancy. (Pubmed Central) -  Nov 12, 2021   
    Sarcopenia is associated with worse progression-free survival and overall survival in gynecological oncology malignancies. Further research is warranted to validate these findings in larger and prospective samples using standardized methodology and to examine if an intervention could reverse its effect in gynecological oncology trials.
  • ||||||||||  Retrospective data, Journal:  Prognostic significance of osteopenia in patients with colorectal cancer: A retrospective cohort study. (Pubmed Central) -  Nov 12, 2021   
    Multivariate analysis indicated that carcinoembryonic antigen >5.0 (P = .04), CA19-9 > 37.0 (P = .05), and osteopenia (P < .01) were significant independent predictors of overall survival. Preoperative osteopenia could be a strong predictor of long-term outcomes in patients undergoing resection for colorectal cancer.
  • ||||||||||  Clinical, Journal:  Clinical impact of sarcopenia assessment in patients with liver cirrhosis. (Pubmed Central) -  Nov 12, 2021   
    Sarcopenia is associated with a higher rate waitlist mortality, hepatic encephalopathy, and lower quality of life in patients with liver cirrhosis. Future studies should make an effort to unify and validate liver disease-specific cut-offs for the definition of sarcopenia.